Betagam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betagam

What is Betagam? Overview

Property Description
Active ingredient Betahistine
Form Oral tablets
Pharmacological class Antivertigo preparation, Histamine analogue
Common use Managing chronic balance disorders
Origin Synthetic substance

What Type of Medicine is Betagam?

Betagam is a synthetic, prescription-only medicine classified as an antivertigo preparation, primarily used for managing chronic balance disorders. The active ingredient is Betahistine, a histamine analogue structurally synthesized to modulate the body’s histaminergic system and central nervous function. Betahistine is used for relieving the symptoms of Ménière's disease and vestibular vertigo by improving blood flow to the inner ear, reducing the frequency of spinning episodes (vertigo). The medicine is utilized to ease discomfort by addressing circulation issues in the inner ear.

Betahistine: Composition and Pharmaceutical Form

The medicine is a single-component product and is supplied as an oral preparation in the form of tablets. The active substance in Betagam is Betahistine, typically utilized as a salt, such as Betahistine dihydrochloride or Betahistine mesylate. This core chemical entity is combined with pharmaceutical excipients suitable for an oral solid dosage form. The availability of Betagam as oral tablets in multiple standardized strengths (e.g., 8 mg, 16 mg, and 24 mg) is a distinguishing feature, making it suitable for the long-term use often required for persistent balance issues.

What is the General Purpose of Betagam?

The general purpose of Betagam is the sustained relief of symptoms related to vestibular disorders, including episodes of vertigo and associated inner ear symptoms. Betahistine is recognized for its ability to enhance blood flow within the inner ear structures and the cochlear region, a mechanism that helps normalize pressure and fluid balance. This targeted physiological effect aids the brain in processing signals from the balance organs, addressing the underlying disturbances responsible for chronic spinning sensations and inner ear discomfort.

Regulatory References

  1. European Commission, Union Register of medicinal products

What side effects are possible with Betagam?

Possible Side Effects and Safety Information

The safety profile of Betagam (Betahistine) is documented through clinical trials and post-marketing surveillance, with adverse reactions classified according to official regulatory frequency standards (e.g., EMA/ICH).


Frequency and System Organ Classes

The most frequently reported adverse reactions are generally related to the gastrointestinal and nervous systems. These reactions are grouped as follows:

Classification System Organ Class Adverse Reactions
Common (1-10 users in 100) Nervous System Disorders Headache
Common Gastrointestinal Disorders Nausea, Dyspepsia (Indigestion)
Not Known Immune System Disorders Hypersensitivity Reactions (e.g., Anaphylaxis)
Not Known Skin and Subcutaneous Disorders Angioneurotic Oedema, Urticaria (Hives), Rash, Pruritus (Itching)

Gastrointestinal complaints, such as mild abdominal pain or vomiting, have been observed. Regulatory safety notes indicate that these effects may be mitigated by taking Betagam with or after a meal.


Serious Adverse Reactions and Safety Constraints

Although rare, Hypersensitivity Reactions are documented as serious adverse reactions, with post-marketing reports including Angioneurotic Oedema (severe swelling).

The official labeling includes specific safety constraints that define conditions where Betagam should not be used or requires special monitoring:

  • Contraindications include a tumor of the adrenal gland called Pheochromocytoma and a known hypersensitivity to the medicine's components.
  • Caution is officially required for patients with a history of Peptic Ulcer or Bronchial Asthma, who require careful monitoring.
  • Use is generally not recommended in the pediatric population, during pregnancy, or while breastfeeding due to insufficient clinical data.

These safety classifications and constraints establish the boundaries for the medicine’s authorized use, defining both the most likely side effects and the specific conditions that may affect its safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this class of medication can lead to serious, life-threatening events, particularly affecting the cardiovascular and central nervous systems. Immediate emergency medical help is required for any suspected or known overdose, regardless of whether symptoms are currently present.

Documented Overdose Presentations

Regulatory documents state that an overdose may result in severe physiological complications. These manifestations primarily include:

  • Cardiovascular: Profound bradycardia (severely slow heart rate), severe hypotension (low blood pressure), heart failure, and cardiogenic shock. Cardiac arrest is a documented risk.
  • Nervous System: Central nervous system (CNS) toxicity may present as confusion, convulsions (seizures), and progression to coma.
  • Other Manifestations: Respiratory issues such as bronchospasm (severe difficulty breathing) and hypoglycemia (dangerously low blood sugar) are also noted, with hypoglycemia being a common and important feature in pediatric overdose.

Risk and Emergency Response

The full severity of an overdose may be delayed, especially following the ingestion of certain sustained-release formulations, which necessitates prolonged medical observation. Overdose is classified as a medical emergency with the potential for fatal outcomes.

If overdose is suspected, immediately contact emergency services or Poison Control for guidance. Treatment is focused on supportive care, which may include monitoring of vital signs, fluid administration, and procedures to support the airway and circulation.

Therapeutic Uses of Betagam

Quick Facts

  • Support for elevated blood pressure (Hypertension): Used to assist in the management of high blood pressure.
  • Angina Pectoris (Chest Pain): Utilized to help prevent episodes of heart-related chest pain.
  • Cardiac Arrhythmias: Indicated for managing certain types of irregular heart rhythms.
  • Migraine Prophylaxis: Employed as a preventive measure to reduce the frequency of migraine headaches.

Betagam is a prescription medication with established therapeutic uses in cardiovascular health and other specific indications. Its primary purpose is to support the management of elevated blood pressure, a condition that may increase the risk of heart and vascular issues. The use of this drug is a component of a comprehensive treatment plan to achieve and maintain appropriate blood pressure levels.

Furthermore, Betagam is indicated for the prevention of angina pectoris, a form of chest discomfort associated with reduced blood flow to the heart muscle. The medication is also utilized in the medical management of certain cardiac arrhythmias, which are characterized by an irregular or abnormal heart rhythm. For individuals experiencing frequent episodes, Betagam may be prescribed for migraine prophylaxis to reduce the occurrence of these headaches. Additional uses include supporting heart health following a myocardial infarction and managing essential tremor.

Eligibility and Restrictions for Use

Eligibility for Betagam (General Principles)

Official regulatory sources define specific patient groups who should or must not use Betagam based on clinical status, age, and pre-existing conditions.

Population Category Eligibility Status (Regulatory Basis)
Contraindicated Patients with known hypersensitivity or a prior severe allergic reaction to the drug or any of its components.
Contraindicated Individuals with bronchial asthma or severe chronic obstructive pulmonary disease (COPD).
Contraindicated Patients with certain serious heart conditions, including sinus bradycardia (abnormally slow heart rate), second- or third-degree atrioventricular (AV) block, and overt cardiac failure.
Restricted Use Individuals with severe renal impairment or end-stage renal disease (ESRD). Use is generally not recommended or requires extreme caution.
Restricted Use Patients with a history of heart failure or a slow/irregular heart rhythm should consult their specialist for an individual assessment before use.

Use in Specific Populations

  • Pediatric Patients: Safety and effectiveness for use in children and adolescents have not been established in regulatory documents.
  • Pregnancy and Lactation: Use during pregnancy is subject to specific assessment of potential risks versus benefits, as the drug may cause harm to the fetus. It is generally advised to consult a healthcare professional, as the drug may be unsafe for use during breastfeeding.
  • Systemic Conditions: Caution is advised for patients with diabetes, hyperthyroidism, or severe gastrointestinal disease. The medicine may mask the common symptoms of low blood sugar or an overactive thyroid.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Betagam is structured around mandated co-administration restrictions and potential pharmacokinetic changes. The medicine is classified as Contraindicated for concurrent use with H₁ Antihistamines due to expected mutual pharmacodynamic antagonism. Use is also contraindicated in patients with phaeochromocytoma, a restriction based on the risk of severe hypertension.

Documented Interaction Patterns

  • Monoamino-oxidase (MAO) inhibitors, including MAO-B selective agents, should be used with caution. Regulatory in vitro data indicates these drugs may inhibit the metabolism of Betagam, a pharmacokinetic mechanism expected to increase the drug's systemic exposure.
  • The medicine is not expected to cause in vivo inhibition of Cytochrome P450 (CYP) enzymes, based on official in vitro data.
  • Food intake is officially documented to slow the rate of absorption, resulting in a lower maximum plasma concentration ( C max), but the total extent of absorption (AUC) remains unchanged.
  • No mandatory timing separation rules are documented, nor are there population-specific interaction cautions regarding severity in hepatic or renal impairment specifically due to co-administered medicines.

Connection to the Overall Interaction Profile

Regulatory documents define the interaction structure by establishing formal prohibitions with certain agents and documenting specific metabolic pathway inhibition concerns. This profile confirms that constraints on co-administration are based on both mutual efficacy concerns (pharmacodynamic) and potential exposure modification risks (pharmacokinetic), reflecting the drug's interaction limitations.

Mechanism of Action

Mechanism of Receptor Blockade

Betagam acts as an antagonist of the interleukin-6 receptor ( IL-6R), resulting in IL-6 signal interruption. This action directly targets the initial step in the inflammatory signaling axis.


Intracellular Signaling Inhibition

This interruption prevents the IL-6-induced activation of the JAK-STAT pathway and other associated signaling cascades. Inhibition of this signaling pathway decreases the transcription and release of acute-phase reactants and other pro-inflammatory cytokines, thereby reducing downstream inflammatory mediators.


Physiological Effects on Bone and Tissue

Modulation of this signaling cascade influences osteoclast and osteoblast activity, resulting in alterations in bone turnover kinetics. This action also decreases inflammatory cytokine expression within the joint synovia.

Dosage and Administration Information

How to Use Betagam — Administration Guidelines

This section describes the administration for the immediate-release formulation of the medication. Standard protocol involves following the prescribed injection schedule and dosing.

Administration Requirements

Usage Domain Instructions
Route and Frequency Administered by subcutaneous injection twice daily (BID).
Timing in Relation to Meals Inject within 60 minutes before the morning meal and the evening meal (or two main meals of the day, at least six hours apart). The medicine must not be administered after a meal.
Initial and Maintenance Dosing Therapy is initiated at 5 micrograms (mcg) per dose twice daily for at least one month. After one month, the dose is increased to 10 mcg twice daily.

Procedural and Special Conditions

The medicine is supplied in a prefilled pen for injection into the thigh, abdomen, or upper arm, and injection sites are rotated with each dose. The liquid is clear and colorless with no particles before use. If a dose is missed, the missed dose is not taken, and the treatment regimen is resumed with the next scheduled dose.

When co-administering this medicine with insulin, the two drugs are administered as separate injections; they are not mixed in the same syringe or pen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Betagam


Evidence for use in Ménière's Disease

Betagam was studied for research contexts involving fluctuating or unstable symptoms of Ménière's disease, a condition characterized by fluctuating or episodic manifestations. The research base includes numerous randomized controlled trials (RCTs), considered a foundational study design for clinical evaluation, alongside systematic reviews that synthesized the existing trial data. These studies primarily involved adults who met the medical criteria for a definite diagnosis of the condition. Researchers explored outcomes related to systemic or functional imbalance, such as tracking the frequency and intensity of vertigo attacks, as well as outcomes reflecting daily functioning or activity level. These were often patient-reported outcomes describing perceived discomfort, such as recordings made in patient diaries.

Research examined how the frequency of vertigo attacks evolved in the observed populations during the study period. Some older studies monitored both groups—those receiving the study drug and those receiving placebo—for changes in the reported frequency and severity of attacks during the observation period. However, findings were mixed when compared against an inactive substance (placebo) in some of the largest, more recent trials. For instance, one major study reported finding no significant difference compared to placebo concerning the rate of attacks. The findings describe patterns observed in the studies but are subject to the challenge that Ménière's disease naturally has fluctuating symptoms, which makes separating a medicine's contribution from the disease's natural course complex.

Evidence for use in Vestibular Vertigo

Research explored the evidence base for Betagam in the broader category of vestibular vertigo of peripheral origin. The studies in this area also included randomized controlled trials that monitored measurements related to systemic or functional imbalance. Researchers evaluated how symptoms like dizziness and general spinning sensations were measured. The populations studied were adults experiencing vertigo arising from peripheral vestibular causes.

In these research scenarios, studies report how symptoms evolved in the observed populations, and earlier evidence reports patterns related to observed symptomatic changes during the study periods. However, the quality of the evidence varies across studies, and many trials in this specific area historically had modest sample sizes. This research contributes to the broader evidence landscape by helping to understand symptom patterns in conditions where symptoms may vary in intensity.


Long-Term Research and Follow-up Durations

Clinical evaluation has included studies with varying follow-up durations. The study drug was evaluated in research scenarios observing defined time intervals that ranged from approximately 90 days to one year. This research examined whether Betagam could be relevant in trials assessing short-term or episodic symptom patterns and also explored its use over longer periods to see how symptom patterns evolved during extended administration. However, the long-term effects are not fully established. There is limited information for long-term outcomes that clearly characterize the durability of any observed changes over multiple years.

Evidence Gaps and Areas of Research Uncertainty

The clinical evidence for Betagam highlights specific areas where certainty remains low and where more research is needed. One major limitation is the inconsistency of results found in large, methodologically sound trials regarding the measured frequency of vertigo attacks in Ménière's disease when compared to placebo. The evidence also provides limited insight into patterns concerning other specific symptoms of Ménière's disease, such as hearing loss or tinnitus. Therefore, while research describes patterns observed in the studied groups, research does not determine whether an individual will respond similarly, and evidence quality varies across studies.

Key Studies & References

  1. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo

Frequently Asked Questions (FAQ)

Common questions about Betagam (FAQ)

Q: How quickly should I expect to feel the effects of Betagam?

A: According to official product information, patients often do not observe an improvement immediately. The effects are sometimes noticed only after a couple of weeks of starting treatment. Observing the full effects of the medication often requires consistent use for a few months.


Q: Are there any long-term side effects associated with Betagam use?

A: The long-term safety profile is derived from clinical trials and post-marketing surveillance data. Most reported adverse reactions are common and mild, such as headache or nausea. However, regulatory documentation indicates that there is limited information available for effects that occur over multiple years of use.


Q: Can Betagam be used by elderly patients?

A: Official prescribing information indicates that a change in dosage is generally not necessary for older patients, based on extensive post-marketing experience. The use of this or any medication in the elderly population is typically overseen by a healthcare professional.


Q: How often is Betagam usually taken?

A: Official administration instructions state that the total daily dosage of Betagam is typically divided. This means the medicine is usually taken in smaller, multiple amounts throughout the day.


Q: What happens if a dose of Betagam is missed?

A: Regulatory guidance suggests that if a dose is missed, it can be taken as soon as the patient remembers, unless the next dose is due shortly. Official patient information explicitly advises against taking a double dose to make up for a missed one.


Q: Can Betagam be crushed or split to make it easier to swallow?

A: Some formulations of the tablets are scored, which allows them to be divided into equal halves. However, the tablets are generally designed to be swallowed whole. Crushing or splitting the tablet should only be done if specifically advised by a prescribing professional.


Q: Does Betagam affect sleep patterns?

A: While not listed among the most common adverse effects, difficulty sleeping has been noted as a possible side effect in post-marketing data. Any changes observed in sleep patterns after beginning treatment should be brought to the attention of the prescribing physician.


Q: Does Betagam have a generic alternative available?

A: Yes, the active ingredient in Betagam, which is called Betahistine, is widely available globally as a generic medicine. It is marketed and sold under various different brand names depending on the manufacturer and country.


Q: How long is a typical course of treatment with Betagam?

A: Treatment with Betagam can be long-term, and the total duration is determined by the patient's response and physician's assessment. Official sources note that observing the full benefit of symptom management sometimes requires continuous use for a few months.


Q: Is Betagam effective for managing chronic conditions?

A: Yes, the primary use of Betagam is to manage symptoms associated with chronic balance disorders, including Meniere's syndrome and various forms of vestibular vertigo.


Q: Are there any warnings about driving or operating machinery while on Betagam?

A: Clinical studies designed to evaluate driving performance found that Betagam itself had no or negligible effects. However, the underlying condition it treats, such as vertigo, can negatively affect these abilities, so caution is advised.


Q: Can Betagam be taken with common vitamins like Vitamin C or D?

A: No specific studies have been performed to check for interactions between Betagam and common vitamins like C or D. Regulatory guidance generally advises caution when using the medicine with any non-prescription remedies or supplements. This topic is best discussed with a healthcare provider.


Q: Can I stop taking Betagam suddenly, or does it require tapering?

A: Regulatory documents do not provide specific instructions regarding tapering or gradually reducing the dose. Stopping any prescribed medication, including Betagam, should be done only after consulting with a healthcare provider.


Q: What are the signs that Betagam is working?

A: Betagam is used to help reduce the frequency and severity of vertigo attacks, which are the spinning sensations associated with inner ear disorders. It may also help with associated symptoms like ringing in the ears (tinnitus) and hearing loss.


Q: What are the most commonly reported side effects of Betagam?

A: Based on clinical data, the most frequently reported side effects are generally mild. These common effects, affecting 1 to 10 users in 100, include headache, nausea, and dyspepsia (indigestion).


Q: Can Betagam cause stomach upset or nausea?

A: Yes, nausea and dyspepsia (stomach upset/indigestion) are listed as common side effects of Betagam. Regulatory safety notes suggest that taking the medication with or after a meal may help mitigate these mild stomach complaints.


Q: Is it necessary to take Betagam with food?

A: Betagam is preferably taken with meals. While not mandatory for efficacy, official product information suggests that taking the dose with or immediately after food may help lessen the potential for gastrointestinal complaints, such as stomach pain or nausea.


Q: Does Betagam interact with birth control pills?

A: Regulatory information indicates that specific interaction studies between Betagam and hormonal birth control pills have not been performed. The known interaction profile primarily focuses on H1 antihistamines and certain metabolism-affecting drugs.


Q: Does Betagam affect blood pressure readings?

A: The official safety profile advises caution regarding blood pressure in certain circumstances. Betagam is contraindicated in patients with a specific adrenal gland tumor (phaeochromocytoma) due to the risk of severe hypertension, and caution is advised in patients who have severe low blood pressure (hypotension).


Q: Is Betagam known to cause weight gain or loss?

A: Official regulatory documents and safety profiles do not list weight gain or weight loss among the common or reported adverse effects of the medicine.


Q: Does Betagam make you sensitive to the sun?

A: The official side effect profile of Betagam does not include photosensitivity or increased sun sensitivity as a reported adverse reaction.


Q: Why do some people experience headaches when taking Betagam?

A: Headache is listed in the official documents as a Common adverse effect, meaning it is one of the most frequently reported side effects. However, the specific reason or biological mechanism for why it occurs is not detailed in the product information.

How should Betagam be stored and disposed of?

Official Storage Requirements

Betagam (Betahistine) tablets must be stored according to the requirements stated in the official regulatory documents to maintain product stability. The required storage environment is generally controlled room temperature, typically stipulated as below 25, C or 30, C. The tablets must be kept in the original container or blister pack and protected from excessive moisture and heat.

Child Safety and Handling

All regulatory labels mandate a Child Safety Mandate: Betagam must be stored out of the sight and reach of children.

Disposal Instructions

To discard unused or expired Betagam, do not throw the product away with household waste or wastewater. The official instruction is to return the medicine to a pharmacist or a designated pharmaceutical waste collection point. This ensures regulated disposal and minimizes environmental impact.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betagam found in:

A-Z Index: